July 30 (Reuters) - Drugmaker Eli Lilly and privately held contract manufacturer Resilience will invest $750 million ‌to expand pharmaceutical manufacturing capacity in the ‌U.S. • Resilience said the investment will increase the production ⁠of critical medicines and create 400 new high-skilled jobs in the Cincinnati, Ohio region. • The company's manufacturing ​operations in ​the region will now ​include Lilly's KwikPen injectable ‌device for treating diabetes and obesity, it added. • The multi-year manufacturing partnership between Lilly and Resilience, which began in 2023, has already produced more than 150 million doses of medicines for U.S. patients in ‌vial and pre-filled syringe formats, ​according to Resilience. • Lilly's manufacturing ​head Edgardo Hernandez ​said the partnership reflects the drugmaker's ‌efforts to meet rising demand ​for its medicines.